摘要
目的:了解LKB1蛋白在肺腺癌组织中表达的临床意义。方法:应用免疫组化法检测62例肺腺癌组织中LKB1蛋白表达情况。结果:LKB1蛋白在肺腺癌细胞及正常肺支气管上皮均有表达,弥漫性分布于细胞质,细胞核亦有表达。肺腺癌组织中LKB1蛋白表达的阴性率为38.7%(24/62)。LKB1的表达与肺腺癌TNM分期中的淋巴结转移(N)及临床分期有显著的相关性,χ2=10.620,P=0.014;χ2=18.635,P=0.000。LKB1蛋白阴性组预后较差,中位生存期为15个月,而LKB1阳性组的中位生存时间为29个月,两者比较差异有统计学意义,χ2=15.350,P=0.000。结论:LKB1蛋白表达下降与肺腺癌发生淋巴结转移相关,是肺腺癌预后不良的风险因素之一。
OBJECTIVE: To study the expression of LKB1 protein and its clinical significance in lung adenocarcinomas. METHODS: Immunohistochemical staining was performed with LKB1 antibody to the surgically resected tissue samples from 62 patients with lung adenocarcinoma. RESULTS: The negative rate of the expression LKB1 protein in lung adenocinoma was 38.7% (24/62). The expression LKB1 protein was associated with the extent of lymph node metastasis ( X^2 = 10. 620, P = 0. 014) and clinical stages,X^2 = 18. 635 ,P=0. 000. The median survival time was 15 months in the LKB1 protein negative expression group, however, 29 months in the LKB1 protein positive expression group,X^2 = 15. 350,P=0. 000. CONCLUSION: Loss LKB1 expression in lung adenocarcinoma may contribute to the lymph node metastasis, and this may be a risky factor for the prognosis of patients with lung adenocarcinoma.
出处
《肿瘤防治杂志》
2005年第17期1281-1284,共4页
China Journal of Cancer Prevention and Treatment
基金
国家自然科学基金(30270590)
关键词
肺肿瘤
腺癌
基因
抑制
肿瘤
预后
免疫组织化学
lung neoplasms
adenocarcinoma
genes, suppressor, tumor
prognosis
immunohistochemistry